83624-01-5

Basic information

• Product Name: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid
• Synonyms: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid;(4R)-1-Boc-4-methoxy-L-proline
• CAS NO: 83624-01-5
• Molecular Formula: C₁₁H₁₉NO₅
• Molecular Weight: 245.27226
• Mol File: 83624-01-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 362.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.75±0.40(Predicted)
• CAS DataBase Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(83624-01-5)
• EPA Substance Registry System: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(83624-01-5)

Safety Data

• Hazardous Substances Data: 83624-01-5(Hazardous Substances Data)

Usage

General Description

The chemical "(2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid" is a compound with a molecular formula C11H19NO5. It is a derivative of pyrrolidine-2-carboxylic acid, with a tert-butoxycarbonyl protecting group attached to the nitrogen atom and a methoxy group attached to the carbon atom. The compound has a stereochemistry of 2S,4R, indicating the positions of the substituents on the pyrrolidine ring. It is commonly used in organic synthesis and as a building block for the preparation of various chemical compounds. The tert-butoxycarbonyl group is often added to protect the amine functionality of the compound, allowing for selective reactions and subsequent removal of the group under specific conditions. Overall, "(2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid" is an important intermediate in organic chemistry with various applications.

Upstream product

• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 67-63-0 isopropyl alcohol 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 96522-36-0 (2S,4R)-4-methoxypyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 426844-31-7 methyl 1-(tert-butoxycarbonyl)-(4R)-methoxypyrrolidine-(2S)-carboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 886447-79-6 ethyl [1-[1-(tert-butoxycarbonyl)-(4R)-methoxy-(2S)-pyrrolidinylcarbony]-4-piperidinyl]acetate 
• 75176-09-9 (2S,4R)-4-methoxypyrrolidine-2-carboxylic acid 
• 1445591-89-8 (2S,4R)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxypyrrolidine-carboxylate 
• 1445591-90-1 methyl ((S)-1-((2S,4R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxypyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1445590-75-9 methyl ((S)-1-((2S,4R)-4-methoxy-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1178549-19-3 N-tert-butoxycarbonyl-(2S,4R)-4-methoxyprolylglycine benzyl ester 
• 886447-59-2 ethyl [1-[(4R)-methoxy-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-4-piperidinyl]acetate 
• 886447-47-8 ethyl 4-[4-methoxy-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-1-piperazinylacetate 
• 1609261-26-8 (S)-1-((2S,4R)-1-(4-(benzyloxy)-3,5-dimethoxybenzoyl)-4-methoxypyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile 
• 1609261-17-7 (2S,4R)-1-(4-(benzyloxy)-3,5-dimethoxybenzoyl)-4-methoxy-pyrrolidine-2-carboxylic acid 

Relevant articles and documents

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

N-methyl-D-aspartate receptor modulators and methods of making and using same

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2

Transglutaminase 2 (TG2) is a ubiquitously expressed enzyme that catalyzes the posttranslational modification of glutamine residues on protein or peptide substrates. A growing body of literature has implicated aberrantly regulated activity of TG2 in the pathogenesis of various human inflammatory, fibrotic, and other diseases. Taken together with the fact that TG2 knockout mice are developmentally and reproductively normal, there is growing interest in the potential use of TG2 inhibitors in the treatment of these conditions. Targeted-covalent inhibitors based on the weakly electrophilic 3-bromo-4,5-dihydroisoxazole (DHI) scaffold have been widely used to study TG2 biology and are well tolerated in vivo, but these compounds have only modest potency, and their selectivity toward other transglutaminase homologues is largely unknown. In the present work, we first profiled the selectivity of existing inhibitors against the most pertinent TG isoforms (TG1, TG3, and FXIIIa). Significant cross-reactivity of these small molecules with TG1 was observed. Structure-activity and -selectivity analyses led to the identification of modifications that improved potency and isoform selectivity. Preliminary pharmacokinetic analysis of the most promising analogues was also undertaken. Our new data provides a clear basis for the rational selection of dihydroisoxazole inhibitors as tools for in vivo biological investigation.